The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Combined Treatment of an Amyotrophic Lateral Sclerosis Rat Model with Recombinant GOT1 and Oxaloacetic Acid: A Novel Neuroprotective Treatment
Abstract
Background/Aim: The sporadic form of the disease affects the majority of amyotrophic lateral sclerosis (ALS) patients. The role of glutamate (Glu) excitotoxicity in ALS has been extensively documented and remains one of the prominent hypotheses of ALS pathogenesis. In light of this evidence, the availability of a method to remove excess Glu from brain and spinal cord extracellular fluids without the need to deliver drugs across the blood-brain barrier and with minimal or no adverse effects may provide a major therapeutic asset, which is the primary aim of this study. Methods: The therapeutic efficacy of the combined treatment with recombinant Glu-oxaloacetate-transaminase (rGOT) and its co-factor oxaloacetic acid (OxAc) has been tested in an animal model of sporadic ALS. Results: We found that OxAc/rGOT treatment provides significant neuroprotection to spinal cord motor neurons. It also slows down the development of motor weakness and prolongs survival. Conclusion: In this study we bring evidence that the administration of Glu scavengers to rats with sporadic ALS inhibited the massive death of spinal cord motor neurons, slowed the onset of motor weakness and prolonged survival. This treatment may be of high clinical significance for the future treatment of chronic neurodegenerative diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GOT1, which was upregulated in the miR-146a KO microglia, is a transaminase enzyme, which has previously been shown to be neuroprotective in animal models of amyotrophic lateral sclerosis (ALS) and cerebral ischemia, regulating the level of extracellular glutamate (58, 59).”
From Absence of miRNA-146a Differentially Alters Microglia Function and Proteome (2020) · cites this paper as [59]
Citations
Cites
Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis
Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J., & Kuncl, R. W. (1995) · Annals of Neurology · doi:10.1002/ana.410380114 · Cited by 1,471
Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1
Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama, E., Reaume, A. G., Scott, R. W., & Cleveland, D. W. (1998) · Science · doi:10.1126/science.281.5384.1851 · Cited by 1,228
Decreased Glutamate Transport by the Brain and Spinal Cord in Amyotrophic Lateral Sclerosis
Rothstein, J. D., Martin, L. J., & Kuncl, R. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262204 · Cited by 1,177
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub3 · Cited by 1,058
Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?
Ikonomidou, C., & Turski, L. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00164-3 · Cited by 721
Glutamate release promotes growth of malignant gliomas
Takano, T., Lin, J. H.-C., Arcuino, G., Gao, Q., Yang, J., & Nedergaard, M. (2001) · Nature Medicine · doi:10.1038/nm0901-1010 · Cited by 601
Trotti, D., Rolfs, A., Danbolt, N. C., Brown, R. H., & Hediger, M. A. (1999) · Nature Neuroscience · doi:10.1038/8091 · Cited by 373
Autocrine Glutamate Signaling Promotes Glioma Cell Invasion
Lyons, S. A., Chung, W. J., Weaver, A. K., Ogunrinu, T., & Sontheimer, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2034 · Cited by 342
Heath, P. R., & Shaw, P. J. (2002) · Muscle & Nerve · doi:10.1002/mus.10186 · Cited by 336
Progression of ischaemic stroke and excitotoxic aminoacids
Castillo, J., Dávalos, A., & Noya, M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)04453-4 · Cited by 320
Inhibition of Cystine Uptake Disrupts the Growth of Primary Brain Tumors
Chung, W. J., Lyons, S. A., Nelson, G. M., Hamza, H., Gladson, C. L., Gillespie, G. Y., & Sontheimer, H. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5258-04.2005 · Cited by 316
Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists
MUIR, K. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.12.002 · Cited by 312
Spreux-Varoquaux, O., Bensimon, G., Lacomblez, L., Salachas, F., Pradat, P. F., Le Forestier, N., Marouan, A., Dib, M., & Meininger, V. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00661-x · Cited by 283
Shaw, P. J., Forrest, V., Ince, P. G., Richardson, J. P., & Wastell, H. J. (1995) · Neurodegeneration · doi:10.1006/neur.1995.0026 · Cited by 269
Cleveland, D. W. (1999) · Neuron · doi:10.1016/s0896-6273(00)81108-3 · Cited by 227
Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans
Baker, A. J., Moulton, R. J., MacMillan, V. H., & Shedden, P. M. (1993) · Journal of Neurosurgery · doi:10.3171/jns.1993.79.3.0369 · Cited by 204
Silver diagnosis in neuropathology: principles, practice and revised interpretation
Uchihara, T. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0200-2 · Cited by 202
Blood‐mediated scavenging of cerebrospinal fluid glutamate
Gottlieb, M., Wang, Y., & Teichberg, V. I. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01972.x · Cited by 171
Self-citationNeuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: An experimental study
Campos, F., Sobrino, T., Ramos‐Cabrer, P., Argibay, B., Agulla, J., Pérez‐Mato, M., Rodríguez‐González, R., Brea, D., & Castillo, J. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.3 · Cited by 142
Glutamate Release and Cerebral Blood Flow After Severe Human Head Injury
Zauner, A., Bullock, R. M., Kuta, A. J., Woodward, J., & Young, H. F. (1996) · Springer eBooks · doi:10.1007/978-3-7091-6894-3_9 · Cited by 136
Relationship between Excitatory Amino Acid Release and Outcome after Severe Human Head Injury
Koura, S., DOPPENBERG, E. M. R., Marmarou, A., Choi, S., Young, H. F., & Bullock, R. M. (1998) · Springer eBooks · doi:10.1007/978-3-7091-6475-4_70 · Cited by 126
Riluzole, a glutamate release inhibitor, and motor behavior
Kretschmer, B. D., Kratzer, U., & Schmidt, W. (1998) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005241 · Cited by 107
Brain neuroprotection by scavenging blood glutamate
Zlotnik, A. A., Gurevich, B., Tkachov, S., Maoz, I., Shapira, Y., & Teichberg, V. I. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.021 · Cited by 106
Self-citationKnockdown of GluR1 expression by RNA interference inhibits glioma proliferation
de Groot, J., Piao, Y., Lu, L., Fuller, G. N., & Yung, W. K. A. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9552-2 · Cited by 93
Trotti, D., Rolfs, A., Danbolt, N. C., Brown, R. H., & Hediger, M. A. (1999) · Nature Neuroscience · doi:10.1038/12227 · Cited by 74
Zlotnik, A. A., Gurevich, B., Cherniavsky, E., Tkachov, S., Ruban, A., Leon, A., Shapira, Y., & Teichberg, V. I. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9548-x · Cited by 71
Self-citationGuyot, L. L., Diaz, F. G., O’Regan, M. H., McLeod, S., Park, H., & Phillis, J. W. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01510-5 · Cited by 69
Oxaloacetate: A novel neuroprotective for acute ischemic stroke
Campos, F., Sobrino, T., Ramos‐Cabrer, P., & Castillo, J. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.11.003 · Cited by 66
Pérez-Mato, M., Ramos-Cabrer, P., Sobrino, T., Blanco, M., Ruban, A., Mirelman, D., Menendez, P., Castillo, J., & Campos, F. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.507 · Cited by 66
Self-citationRichards, D. A., Tolias, C. M., Sgouros, S., & Bowery, N. G. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00081-1 · Cited by 62
Boyko, M., Zlotnik, A. A., Gruenbaum, B. F., Gruenbaum, S. E., Ohayon, S., Kuts, R., Melamed, I., Regev, A., Shapira, Y., & Teichberg, V. I. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07864.x · Cited by 54
Self-citationCampos, F., Pérez‐Mato, M., Agulla, J., Blanco, M., Barral, D., Almeida, Á., Brea, D., Waeber, C., Castillo, J., & Ramos‐Cabrer, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044191 · Cited by 52
Sun, H. J., Kawahara, Y., Ito, K., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03903.x · Cited by 51
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas
Ruban, A., Berkutzki, T., Cooper, I., Mohar, B., & Teichberg, V. I. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9794-x · Cited by 46
Self-citationMalignant glioma—induced neuronal cell death in an organotypic glioma invasion model
Eyüpoglu, I. Y., Hahnen, E., Heckel, A., Siebzehnrübl, F. A., Buslei, R., Fahlbusch, R., & Blümcke, I. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.102.4.0738 · Cited by 41
Tsai, P., & Huang, P. (2000) · Journal of Nutrition · doi:10.1093/jn/130.4.1002s · Cited by 40
Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis.
Andreadou, E., Kapaki, E. N., Kokotis, P., Paraskevas, G. P., Katsaros, N., Libitaki, G., Petropoulou, O., Zis, V., Sfagos, C., & Vassilopoulos, D. (2008) · PubMed · Cited by 38
NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia
Feng, J.-F., Gurkoff, G. G., Van, K. C., Song, M., Lowe, D. A., Zhou, J., & Lyeth, B. G. (2012) · Brain Research · doi:10.1016/j.brainres.2012.06.021 · Cited by 33
Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model
Park, J., Hong, Y., Kim, H., Kim, S., Kim, M.-J., Park, K. S., Sung, J., & Lee, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.11.058 · Cited by 32
Blood Glutamate Scavenging as a Novel Neuroprotective Treatment for Paraoxon Intoxication
Ruban, A., Mohar, B., Jona, G., & Teichberg, V. I. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.186 · Cited by 25
Self-citationGlutamine drives glucose-independent TCA cycle
Le, A. (2012) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.s1.021 · Cited by 1
Cited by
Absence of miRNA-146a Differentially Alters Microglia Function and Proteome
Martin, N. A., Hyrlov, K. H., Elkjaer, M. L., Thygesen, E. K., Wlodarczyk, A., Elbaek, K. J., Aboo, C., Okarmus, J., Benedikz, E., Reynolds, R., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01110 · Cited by 36
Metadata
- Authors
- Ruban, A., Cohen-Kashi Malina, K., Cooper, I., Graubardt, N., Babakin, L., Jona, G., & Teichberg, V. I.
- ORCID
- Ruban, Angela
- Venue
- Neurodegenerative Diseases
- Publisher
- S. Karger AG
- Published
- 2015
- Volume
- 15
- Issue
- 4
- Pages
- 233-242
- ISSN
- 1660-2854
- 1660-2862
- Cited by
- 39
- References
- 41
- Language
- en
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
